Cargando…

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

OBJECTIVE: This study aimed to examine the prevalence and prognostic role of tumor microenvironment (TME) in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) through immunohistochemical characterization. METHODS: The internal database of the Brazilian National Cancer Instit...

Descripción completa

Detalles Bibliográficos
Autores principales:	da Silva, Jesse Lopes, de Albuquerque, Lucas Zanetti, Rodrigues, Fabiana Resende, de Mesquita, Guilherme Gomes, Fernandes, Priscila Valverde, Thuler, Luiz Claudio Santos, de Melo, Andreia Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630741/ https://www.ncbi.nlm.nih.gov/pubmed/34858800 http://dx.doi.org/10.3389/fonc.2021.636716

Ejemplares similares

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications
por: da Silva, Jesse Lopes, et al.
Publicado: (2023)

The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy
por: Bai, Yu-Ge, et al.
Publicado: (2020)

Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort
por: da Silva, Jesse Lopes, et al.
Publicado: (2020)

Exploring biomarkers and prognostic factors in uterine carcinosarcoma: An insight into L1CAM, CDX2, p53, and MSI status
por: da Silva, Jesse Lopes, et al.
Publicado: (2023)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
por: Wang, Ruo-Xi, et al.
Publicado: (2022)

Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
por: Silva, Diogo, et al.
Publicado: (2022)

A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2023)

Overview of Adult Sarcoma Burden and Clinical Pathways in Brazil
por: David, Bruna Bianca Lopes, et al.
Publicado: (2022)

Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer
por: Delmonico, Lucas, et al.
Publicado: (2023)

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
por: Lehmann, Brian D., et al.
Publicado: (2016)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
por: Wang, Yihua, et al.
Publicado: (2021)

Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype
por: Harano, Kenichi, et al.
Publicado: (2018)

Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast
por: Jamiyan, Tsengelmaa, et al.
Publicado: (2020)

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
por: Luen, Stephen L., et al.
Publicado: (2019)

Epidemiological profile of mucosal melanoma in Brazil
por: Cohen Goldemberg, Daniel, et al.
Publicado: (2020)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Herrero-Vicent, Carmen, et al.
Publicado: (2017)

Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis
por: Cao, Bo, et al.
Publicado: (2023)

Gynecologic cancer in Brazil and the law of sixty days
por: Paulino, Eduardo, et al.
Publicado: (2018)

Epidemiology of uveal melanoma in Brazil
por: Lucena, Evandro, et al.
Publicado: (2020)

Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors
por: Brandi, Andressa, et al.
Publicado: (2022)

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
por: Ruan, Miao, et al.
Publicado: (2018)

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
por: Asano, Yuka, et al.
Publicado: (2017)

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
por: Anand, Kartik, et al.
Publicado: (2021)

An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
por: Blaye, C., et al.
Publicado: (2022)

Prognostic significance of tumor-infiltrating CD8(+) and FOXP3(+) lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study
por: Miyashita, Minoru, et al.
Publicado: (2015)

Panorama of Gynecologic Cancer in Brazil
por: Paulino, Eduardo, et al.
Publicado: (2020)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Assessment of Intratumoural and Stromal Infiltrating Lymphocytes in the Various Subtypes of Breast Carcinoma Patients who have Received Neoadjuvant Chemotherapy
por: Rangan, Rahul, et al.
Publicado: (2023)

The Value of Tumor Infiltrating Lymphocytes (TIL) for Predicting the Response to Neoadjuvant Chemotherapy (NAC) in Breast Cancer according to the Molecular Subtypes
por: Faur, Ionut Flaviu, et al.
Publicado: (2023)

Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
por: Lejeune, Marylène, et al.
Publicado: (2023)

The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy
por: Elmahs, Aya, et al.
Publicado: (2022)

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy
por: Hamy, Anne-Sophie, et al.
Publicado: (2020)

Prognostic factors associated with overall survival in patients with oral cavity squamous cell carcinoma
por: Oliveira, Letícia L., et al.
Publicado: (2020)

Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
por: Masuda, Hiroko, et al.
Publicado: (2022)

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes
por: de Ronde, Jorma J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_viinhrqbganka1h01mg1gpa2e8